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Exhaled nitric oxide (eNO) detects airway inﬂammation. Hyperbaric oxygen therapy (HBOT) is used for tissue hypoxia, but can
cause lung damage. We measured eNO following inhalation of oxygen at diﬀerent tensions and pressures. Methods.P a r t1 ,e N O
was measured before and after HBOT. Part 2, normal subjects breathed 40% oxygen. Results. Baseline eNO levels in patients prior
toHBOTexposureweresigniﬁcantlyhigherthaninnormalsubjects(P <.05).AfterHBOT,eNOsigniﬁcantlydecreasedinpatients
(15.4 ± 2.0 versus 4.4 ± 0.5ppb, P<.001), but not in normal subjects, after either 100% O2 at increased pressure or 40% oxygen,
1 ATA. In an in vitro study, nitrate/nitrite release decreased after 90 minutes HBOT in airway epithelial (A549) cells. Conclusion.
HBO exposure causes a fall in eNO. Inducible nitric oxide synthase (iNOS) may cause elevated eNO in patients secondary to
inﬂammation, and inhibition of iNOS may be the mechanism of the reduction of eNO seen with HBOT.
Copyright © 2006 Zudin A. Puthucheary et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Exhaled nitric oxide (eNO) is a marker of airway inﬂamma-
tion [1]. Although NO is produced in the airways by a va-
riety of cells, large amounts may be generated from those
involved in the acute and chronic inﬂammatory responses
[2]. NO plays a role in pulmonary host defence mechanisms,
andisthoughttohavebothbactericidalandbacteriostaticef-
fects [3, 4]. Exhaled NO is released by nitric oxide synthases
(NOS), including neuronal NOS (nNOS, Type 1), inducible
NOS (iNOS, Type 2), and endothelial NOS (ecNOS, Type 3).
These NOS isoforms have been demonstrated in the airways
of many mammalian species including man [5, 6]. iNOS is
generally not expressed unless the cells have been induced by
certain cytokines, however, when stimulated, high concen-
trations (μM) of NO are produced [7–9]. Thus, an increase
in exhaled NO may be due to upregulation of iNOS within
epithelialcellsinresponsetoproinﬂammatorycytokinesand
oxidants [10, 11].
In recent years, eNO has been used as a sensitive marker
of asthmatic airway inﬂammation [12, 13] .T h ea s s a yi se a s y
to perform and reproducible with clinically useful sensitivity
and speciﬁcity [1].
Hyperbaric oxygen therapy (HBOT) is used for the treat-
ment of a number of conditions associated with tissue hy-
poxia, including late radiation tissue injury and diabetic
foot ulcers. These conditions are associated with hypoxia
at the site of disease, and improving oxygenation may as-
sist in the resolution of these lesions. Despite these ben-
eﬁcial eﬀects, HBOT is associated with some undesirable
side eﬀects. Hyperoxia has long been associated with tis-
sue damage and the development of lung diseases. The
mechanism is not fully understood, but may be attributed
to reactive oxygen species (producing oxygen free radicals,
ROS) which induce the pulmonary cytochrome P450 en-
zymes [14–16]. This is supported by animal research into
neonatal bronchopulmonary dysplasia, which has shown
an arrest in alveolar and capillary development in posi-
tive pressure ventilated animals [17]. It has been reported
that ventilation with atmospheric hyperoxia in isolated per-
fused lungs increased NO generation [18, 19]. Conﬂicting
reports in the literature have been described in studies of
humans breathing 100% O2 [20, 21]. These changes asso-
ciated with hyperoxia have been explained by the bonding
of oxygen free radicals (O·) to extracellular NO in the body
generating peroxynitrite (ONOO−)w h i c hi sas t r o n go x -
idant and which has been reported to increase iNOS ex-
pression [22–25]. However, not all studies are consistent
with these ﬁndings and hyperbaric oxygenation (HBO) has
been shown to decrease NO generation in animal models2 Mediators of Inﬂammation
of shock, perhaps via a decrease in the activity of iNOS
[26].
This study aimed to measure alterations in eNO follow-
ing a standard hyperbaric oxygen regime in those with tis-
sue hypoxia and to compare them with normal subjects who
were either attendants in the HBO chamber or who breathed
supplementaloxygenatsealevel.Itwashypothesisedthathy-
peroxia could downregulate exhaled nitric oxide. In addition
it was hypothesised that the changes in eNO would be re-
ﬂected in the ability of isolated pulmonary cells to generate
nitriteinvitroundersimilarconditionsasexperiencedbythe
patients.
METHODS
Subjects
Following the ethics committee’s approval of the experimen-
tal protocol and written informed consent, patients under-
going HBO at the Prince of Wales Hospital Department of
Diving and Hyperbaric Medicine were recruited to the study.
All patients were undergoing HBOT for medical indications
and no patient was subjected to HBOT purely for the sake
of the study. These subjects were asked to complete a ques-
tionnairedetailingtheirmedicalhistory,currentmedications
(particularly the use of glucocorticosteroids or nonsteroidal
anti-inﬂammatory agents (NSAIDS)), and speciﬁc questions
regarding the diagnoses of asthma, chronic obstructive pul-
monary disease or other pulmonary diseases, diabetes mel-
litus, and ischemic heart disease. Smoking history was ob-
tained. Normal subjects were recruited from hospital staﬀ
and also completed the same questionnaire.
Exhalednitricoxidemeasurements
The sampling and measurement procedure was as follows:
subjects were asked to inhale orally and exhale into a 2-liter
gas impermeable bag with a one way valve, generating a pos-
itive pressure to close the velum [27, 28]. If unable to ﬁll this
in one breath, a second breath was used. The samples were
then analysed within 60 minutes using a closed gas circuit
connected to a chemiluminescent nitric oxide analyser, (Da-
sibi Environmental Corp, Glendale, Calif, USA) for NO and
Spacelabs Capnograph Model 90513-30 (Redmond, Wash,
USA) for CO2. The values obtained are therefore an average
of mixed expired gas concentrations of one or two expira-
tions.
Protocol
Part one
All patients and attendants provided an expired NO sample
prior to compression, the patients then underwent a stan-
dard 90-minute HBOT session at 2.4 atmospheres absolute
(ATA), breathing 100% O2. These sessions involve a ﬁve
to ten minute compression phase breathing air, 90 minutes
breathing 100% oxygen at 2.4 ATA by demand valve mask or
hood, and a further 20 minutes slow decompression while
continuing to breathe oxygen. The total time in the cham-
ber for each session is therefore approximately two hours.
During this period they were accompanied by a trained hy-
perbaric chamber nursing attendant who breathed air dur-
ing the compression and 2.4 ATA periods, before starting
100% oxygen for the 20-minute decompression phase. This
is a standard operating procedure to reduce the risk of de-
compression illness for the attendant. For our experimen-
tal protocol, the attendants supplied a further sample of ex-
pired gas at 2.4 ATA before starting their oxygen breathing
period.
Immediately on exiting the hyperbaric chamber, a fur-
ther exhaled NO sample was taken from patients and staﬀ.
Part two
A separate section studied normal subjects breathing 40%
oxygen for 90 minutes via a face mask at 1 ATA. Exhaled NO
samples were collected every 15 minutes.
Part three
A549 cells, an immortalised cell line derived from a lung ep-
ithelial cell carcinoma, were used as a model of airway ep-
ithelium. These cells have been demonstrated to be able to
express iNOS and to be able to generate nitrite [29]. Four
plates of 2 − 4 × 106 A549 cells were incubated in F12-K
media with 10% foetal calf serum (FCS) and exposed to
the following conditions for 90min: (a) room temperature
and ambient air (plate A); (b) 100% oxygen at normal pres-
sure (plate B); (c) air at 2.4 ATA pressure (plate C); and
(d) 100% oxygen at 2.4 ATA (plate D). Interferon gamma
is known to stimulate A549 cells to increase NO produc-
tion [30]. Under each of the conditions, A549 cells were
therefore cultured in media with 0, 10, and 20ng/mL re-
combinant human interferon gamma (hIFN γ,S e r o t e cL t d ,
UK). Nitrite/nitrate (NOx) was measured by using a ﬂuores-
cent method [31]. Samples were mixed with NADPH, FAD
(Sigma, Sydney, Australia), and nitrate reductase with a ﬁ-
nal concentration of 50μM, 5μM, and 50IU/L, respectively,
and incubated in 37◦C for 1h, which allows nitrate to be
converted to nitrite. Nitrite was conjugated with 0.05mg/mL
2,3-diaminonaphthalene (DAN) in 0.62M HCL to allow
quantiﬁcation by ﬂuorescence. The reaction was terminated
with 2.8M NaOH. The resultant ﬂuorescence was immedi-
ately read on a CytoFluro Series 4000, Multiwell Plate Reader
(Perseptive Biosystems, Mass, USA) at excitation 360/40,
emission 395/25, gain 50, limit of detection 2μmol/L, mean
(SD) intra-assay coeﬃcient of variation 3.11(3.42)%. Data
are expressed as % change from baseline.
Analysis
Data are presented as mean ± SE. The results were analysed
using changes in NO (ppb) and CO2 (mmHg), after the NO
values were log transformed to the normal distribution [13].
Student’s t test was used to calculate P-values, which were
considered signiﬁcant if P<. 05.Zudin A. Puthucheary et al 3
Table 1: Subject characteristics.
Patients
(male/female)
Normal controls
(male/female)
Smoker 1/0 0/0
Ex-smoker 0/0 2/0
Nonsmoker 9/5 6/8
Asthma 1/0 0/0
NSAID 2/0 0/0
Steroids 2/1 0/0
Foot ulcers 60
Osteoradionecrosis 70
Dental caries 10
Radiation cystitis 10
Lumbar cord oedema 10
Total 10/5 8/8
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Figure 1: Exhaled nitric oxide levels in 15 patients undergoing
HBOT immediately before and after treatment. There was a sig-
niﬁcant fall in these patients (mean ± SE, before 15.4 ± 2.0ppb,
afterwards 4.4 ±0.5ppb,P<. 001).
RESULTS
Partone
In total, 16 attendants and 15 patients were recruited. Of the
patients, 12 were not on current glucocorticosteroid therapy
and 10 were not current steroid or NSAID users (Table 1).
One attendant omitted to collect a breath sample in the
chamber and other two samples collected in the chamber
werelostduetooverexpansionandultimatefailureofthegas
collection bag during decompression. Mean (SD) coeﬃcient
of variation of interbag exhaled NO levels was 6.36(1.17)%.
The initial mean eNO level in patients was signiﬁcantly
higher than both that in attendants (15.4 ± 2.0ppbvs7.6 ±
1.1ppb,P<. 05) and the normal subjects in Part 2 (5.3 ±
1.0ppb,P<. 01). No diﬀerence in the initial exhaled NO
level was found between the attendants and normal subjects
at 1 ATA (7.6 ±1.1ppbvs5.3 ± 1.0ppb,resp,P = .14).
Patients
eNO signiﬁcantly decreased after HBOT (Figure 1,1 5 .4±2.0
vs 4.4 ± 0.5ppb,P<. 001, n = 15). This eﬀect was present
in both the subgroup not on glucocorticosteroids (15.2±2.3
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Figure 2: Exhaled nitric oxide levels in 16 normal staﬀ members
who were exposed to the hyperbaric environment but did not use
oxygen until immediately prior to decompression. There were no
signiﬁcant changes between the samples.
vs 4.3 ± 0.6ppb,P<. 001, n = 12) and in the subgroup
on neither glucocorticosteroids nor NSAIDs (16.1 ± 2.5v s
4.4 ± 0.6ppb,P<. 001, n = 10). Exhaled CO2 showed a
small but signiﬁcant increase following HBOT in the patient
group (25.5mmHg ±1.0v s2 7 .3mmHg ±0.9, P<. 05).
Attendantsinthehyperbaricchamber
The mean exhaled NO level before hyperbaric exposure was
7.6±1.1ppb and the mean level was 7.9±0.9ppb(Figure 2,
P = .46, n = 16) afterwards.
Parttwo
Normalsubjectsbreathing40%oxygenat1ATA
Mean exhaled NO levels in this normal group of subjects
were 5.3 ± 1.0ppbbeforeand4.6 ± 1.1 after 90-minute 40%
oxygen inhalation (P = .22, n = 8), with no signiﬁcant
change in exhaled NO levels at any of the 15-minute inter-
vals.
Partthree
There was a signiﬁcant decrease in NOx release into the cell
culture media after exposure to 100% oxygen for 90 minutes
in the A549 cells incubated in media alone (32.49% change
from baseline vs 9.38%, P<. 01) and media with 20ng/mL
hIFN γ (33.58% vs 9.25%, P<. 05). The hyperbaric en-
vironment alone did not cause signiﬁcant changes (32.49%
vs 22.80%, P = .32 in media only, and 33.58% vs 20.64%,
P = .29 in media with 20ng/mL hIFN γ).
DISCUSSION
In this study, eNO levels of patients were signiﬁcantly de-
creased after HBOT. In normal subjects eNO did not de-
creasesigniﬁcantlyaftereitherashortexposureto100%oxy-
gen during decompression, or 40% oxygen for 90 minutes
in normal subjects. The decrease in eNO seen in the HBOT
patient group has been observed in studies using oxygen at
1 ATA. For example, Tsuchiya demonstrated inhalation of4 Mediators of Inﬂammation
100%oxygenfor50minutesreducedexhaledNOlevelswhile
inhalation of 40% oxygen in a second group of mechani-
cally ventilated human subjects undergoing surgery did not
[21]. It is possible, however, that endogenous NO might be
aﬀected by anaesthetic agents, surgery, the increased airway
pressure during mechanical ventilation, and these individu-
alsmaynotshowthesameresponseasspontaneouslybreath-
ing individuals. It is worth noting that both our study and
that of Tsuchiya showed that 40% oxygen inhalation did not
changeeNOlevelssigniﬁcantly[21].The40%oxygeninhala-
tion was chosen as it allowed a conventional mask to be used,
but it would have been a more accurate comparison of the
equivalent 2.4 ATA exposure if 50.4% oxygen had been used.
In Part 1 of this study, no signiﬁcant changes in eNO lev-
els were observed in normal subjects after breathing hyper-
baric air at 2.4 ATA for 90 minutes. This exposure is equiv-
alent to breathing 50.4% oxygen at 1 ATA (the inspired pO2
is approximately 361mmHg in each case). Compared with
the hyperbaric oxygen at the same pressure inhaled by the
patients, it could be concluded that pressure is not the main
factor altering the eNO levels in this study, although these
normal subjects had a lower baseline eNO.
The increase in exhaled CO2 in the patients is presum-
ably due to either stimulation of NADPH turnover through
thepentosecycleor,morelikely,suppressionoftheirhypoxic
ventilatory drive [32–34].
The attendants received less hyperbaric oxygen exposure
than the patients and we acknowledge this may bias the re-
sult towards no change in these individuals. In addition, this
groupwasyoungerandgenerallymorephysicallyﬁt.Thelack
ofinﬂammatorydiseasesinbothcontrolgroupsprobablyac-
counts for the diﬀerence in baseline eNO between them and
the patients. Half of the patients had osteoradionecrosis of
the head and neck, initial mean exhaled NO 15.0±2.88ppb,
which may be associated with inﬂammation of the upper air-
way. Those without osteoradionecrosis, however, had a sim-
ilar baseline exhaled NO. The reason for this is unclear but
may be related to inﬂammation associated with their under-
lying condition with foot ulcers being the most common in-
dication for HBOT. These conditions were associated with
an elevated eNO above our normal range [35]. Although
this was a prospective study, patients were recruited at var-
ious times during their HBOT, which may have inﬂuenced
the baseline exhaled NO values. It was hypothesised that
the elevated baseline exhaled NO in the patients was related
to the induction of iNOS. Inducible NOS is generally not
expressed unless the cells have been activated by inﬂamma-
tory cytokines [7–9, 36, 37].
Inhibition of iNOS in patients by HBOT may account for
thedecreaseofeNOlevels.Recentstudieshavedemonstrated
thatoxidativestressalsopreventediNOSinductioninintesti-
nalepithelialcells[38,39].Yuanetalshowedthathyperbaric
oxygen (HBO) suppressed iNOS expression in rabbit chon-
drocytes, and Pedoto et al reported that HBO decreased ex-
haled NO generation, plasma nitrite/nitrate concentration,
and iNOS expression in the rat lung [26, 38, 40]. Absent or
lowlevelsofiNOSinnormalsubjectscouldexplainwhyeNO
levels did not change after oxygen inhalation.
Changes in production of ROS or inhibition of iNOS ex-
pression would be two possible reasons for the decrease in
eNO after inhalation of high concentrations of oxygen for
a long period although no study has addressed the eﬀect of
short exposure to HBOT in terms of oxidative status [41].
ROS generally increase inﬂammation, which would be ex-
pected to increase iNOS expression. It is possible, however,
that ROS could react with NO, and convert it to other NOx
species. This seems unlikely as the in vitro studies showed a
decline in NOx with O2 exposure.
It has been reported that a combination of interferon
gamma and interleukin 4 stimulates and maintains iNOS
expression in human airway epithelium [42]. This study
showed that NOx released from the A549 cell line incubated
in media alone or with 20ng/mL human interferon gamma
signiﬁcantlydecreasedafterexposureto100%oxygen,which
occurredintheabsenceofHBO.Thissuggeststhatinhibition
ofiNOSmaybethemechanismofthereductionineNOseen
in patients. It has been demonstrated that iNOS is expressed
under resting conditions in the A549 cell line, which could
explain the decrease in NOx release after 100% oxygen expo-
sure in the A549 cell line incubated in media only [29].
In conclusion, our resultssuggestthat inhibition of iNOS
may be the mechanism of HBOT-induced reduction in eNO.
This might have beneﬁcial eﬀects on inﬂammation, a ques-
tion which could to be further investigated by measurement
of iNOS expression in a randomized controlled study in re-
sponse to hyperoxia.
ACKNOWLEDGMENT
The participation of patients and Hyperbaric Medicine Unit
staﬀ in the research is gratefully acknowledged.
REFERENCES
[1] Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Repro-
ducibilityofexhalednitricoxidemeasurementsinhealthyand
asthmatic adults and children. European Respiratory Journal.
2003;21(3):433–438.
[2] Yates DH. Role of exhaled nitric oxide in asthma. Immunology
and Cell Biology. 2001;79(2):178–190.
[3] Dukelow AM, Weicker S, Karachi TA, et al. Eﬀects
of nebulized diethylenetetraamine-NONOate in a mouse
model of acute pseudomonas aeruginosa pneumonia. Chest.
2002;122(6):2127–2136.
[4] Hucke C, MacKenzie CR, Adjogble KDZ, Takikawa O,
D¯ aubener W. Nitric oxide-mediated regulation of gamma
interferon-induced bacteriostasis: inhibition and degradation
of human indoleamine 2,3-dioxygenase. Infection and Immu-
nity. 2004;72(5):2723–2730.
[5] Deynin A, Massaro AF, Kobzik L, De Sanctis GT, Drazen JM.
Molecularandcellularsourcesofexhalednitricoxide.In:Mar-
czin N, Kharitonov SA, Yacoub MH, Barnes PJ, eds. Disease
Markers in Exhaled Breath. C h a p t e r3 .N e wY o r k ,N Y :M a r c e l
Dekker; 2003:73–89.
[6] Asano K, Chee CBE, Gaston B, et al. Constitutive and in-
ducible nitric oxide synthase gene expression, regulation, and
activity in human lung epithelial cells. Proceedings of the Na-
tional Academy of Sciences of the United States of America.
1994;91(21):10089–10093.Zudin A. Puthucheary et al 5
[7] Andrew PJ, Mayer B. Enzymatic function of nitric oxide syn-
thases. Cardiovascular Research. 1999;43(3):521–531.
[8] HeckerM,CattaruzzaM,WagnerAH.Regulationofinducible
nitric oxide synthase gene expression in vascular smooth mus-
cle cells. General Pharmacology. 1999;32(1):9–16.
[9] Albrecht EWJA, Stegeman CA, Heeringa P, Henning RH, van
Goor H. Protective role of endothelial nitric oxide synthase.
Journal of Pathology. 2003;199(1):8–17.
[10] Dupuy PM, Frostell CG. Bronchial eﬀects of nitric oxide. In:
Z a p o lW M ,B l o c hK D ,e d s .Nitric Oxide and the Lung. Chap-
ter 15. New York, NY: Mercel Dekker; 1997:285–312.
[11] Karupiah G, Xie Q-W, Buller RML, Nathan C, Duarte C,
MacMicking JD. Inhibition of viral replication by interferon-
γ-induced nitric oxide synthase. Science. 1993;261(5127):
1445–1448.
[12] Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R,
Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled
air of asthmatic patients. Lancet. 1994;343(8890):133–135.
[13] YatesDH,KharitonovSA,RobbinsRA,ThomasPS,BarnesPJ.
Eﬀect of a nitric oxide synthase inhibitor and a glucocorticos-
teroid on exhaled nitric oxide. American Journal of Respiratory
and Critical Care Medicine. 1995;152(3):892–896.
[14] Gerschman R, Gilbert DL, Nye SW, Dwyer P, Fenn WO. Oxy-
gen poisoning and x-irradiation: a mechanism in common.
Science. 1954;119(3097):623–626.
[15] Jamieson D, Chance B, Cadenas E, Boveris A. The relation of
free radical production to hyperoxia. Annual Review of Physi-
ology. 1986;48:703–719.
[16] Couroucli XI, Welty SE, Geske RS, Moorthy B. Regulation
of pulmonary and hepatic cytochrome P4501A expression in
the rat by hyperoxia: implications for hyperoxic lung injury.
Molecular Pharmacology. 2002;61(3):507–515.
[17] Thomson MA, Yoder BA, Winter VT, et al. Treatment of im-
mature baboons for 28 days with early nasal continuous posi-
tive airway pressure. American Journal of Respiratory and Crit-
ical Care Medicine. 2004;169(9):1054–1062.
[18] Nozik ES, Huang Y-CT, Piantadosi CA. L-Arginine enhances
injuryintheisolatedrabbitlungduringhyperoxia.Respiration
Physiology. 1995;100(1):63–74.
[19] Suzuki K, Naoki K, Kudo H, et al. Impaired hypoxic vaso-
constriction in intraacinar microvasculature in hyperoxia-
exposed rat lungs. American Journal of Respiratory and Critical
Care Medicine. 1998;158(2):602–609.
[20] Schmetterer L, Findl O, Strenn K, et al. Role of NO in the O2
and CO2 responsiveness of cerebral and ocular circulation in
humans. American Journal of Physiology - Regulatory Integra-
tive and Comparative Physiology. 1997;273(6):R2005–R2012.
[21] Tsuchiya M, Tokai H, Takehara Y, et al. Interrelation between
oxygen tension and nitric oxide in the respiratory system.
American Journal of Respiratory and Critical Care Medicine.
2000;162(4 pt 1):1257–1261.
[22] Cooke C-LM, Davidge ST. Peroxynitrite increases iNOS
through NF-κB and decreases prostacyclin synthase in en-
dothelialcells.AmericanJournalofPhysiology - CellPhysiology.
2002;282(2):C395–C402.
[ 2 3 ] C u c c h i a r oG ,T a t u mA H ,B r o w nM C ,C a m p o r e s iE M ,
Daucher JW, Hakim TS. Inducible nitric oxide synthase in
the lung and exhaled nitric oxide after hyperoxia. American
Journal of Physiology - Lung Cellular and Molecular Physiology.
1999;277(3):L636–L644.
[24] Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA.
Apparent hydroxyl radical production by peroxynitrite: im-
plications for endothelial injury from nitric oxide and super-
oxide. Proceedings of the National Academy of Sciences of the
United States of America. 1990;87(4):1620–1624.
[25] SatoT,TakedaY,HagiokaS,ZhangS,HirakawaM.Changesin
nitric oxide production and cerebral blood ﬂow before devel-
opment of hyperbaric oxygen-induced seizures in rats. Brain
Research. 2001;918(1-2):131–140.
[26] Pedoto A, Nandi J, Yang Z-J, et al. Beneﬁcial eﬀect of hy-
perbaric oxygen pretreatment on lipopolysaccharide-induced
shock in rats. Clinical and Experimental Pharmacology and
Physiology. 2003;30(7):482–488.
[27] Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric
oxide measurements: recommendations. The European Respi-
ratory Journal. 1997;10(7):1683–1693.
[28] American Thoracic Society. Recommendations for standard-
ized procedures for the online and oﬄine measurement of
exhaled lower respiratory nitric oxide and nasal nitric oxide
in adults and children—1999. American Journal of Respiratory
and Critical Care Medicine. 1999;160(6):2104–2117.
[29] Wei XM, Kim HS, Kumar RK, et al. Eﬀects of cigarette smoke
on degranulation and NO production by mast cells and ep-
ithelial cells. Respiratory Research. 2005;6(1):108.
[30] Robbins RA, Barnes PJ, Springall DR, et al. Expression of in-
duciblenitricoxideinhumanlungepithelialcells.Biochemical
and Biophysical Research Communications. 1994;203(1):209–
218.
[31] Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG.
A ﬂuorometric assay for the measurement of nitrite in biolog-
ical samples. Analytical Biochemistry. 1993;214(1):11–16.
[32] Bassett DJ, Fisher AB. Glucose metabolism in rat lung dur-
ing exposure to hyperbaric O2. Journal of Applied Physiology.
1979;46(5):943–949.
[33] Donina ZhA, Ivanov AS, Troshikhin GV. Compensatory reac-
tionsoftherabbitrespiratorysystemtohypoxicstimulationin
hyperbaric conditions [in Russian]. Aviakosmicheskaia i Eko-
logicheskaia Meditsina. 1996;30(4):34–38.
[34] Fontanari P, Badier M, Guillot Ch, et al. Changes in maximal
performance of inspiratory and skeletal muscles during and
after the 7.1-MPa hydra 10 record human dive. European Jour-
nal of Applied Physiology. 2000;81(4):325–328.
[35] Thomas PS, Gibson PG, Wang H, Shah S, Henry RL. The re-
lationship of exhaled nitric oxide to airway inﬂammation and
responsivenessinchildren.JournalofAsthma.2005;42(4):291–
295.
[36] Morris SM Jr, Billiar TR. New insights into the regulation of
inducible nitric oxide synthesis. American Journal of Physiol-
ogy. 1994;266(6 pt 1):E829–E839.
[37] Meng Q-H, Springall DR, Bishop AE, et al. Lack of inducible
nitricoxidesynthaseinbronchialepithelium:apossiblemech-
anism of susceptibility to infection in cystic ﬁbrosis. Journal of
Pathology. 1998;184(3):323–331.
[38] Yuan L-J, Ueng SWN, Lin S-S, Yeh W-L, Yang C-Y, Lin PY. At-
tenuation of apoptosis and enhancement of proteoglycan syn-
thesis in rabbit cartilage defects by hyperbaric oxygen treat-
ment are related to the suppression of nitric oxide production.
Journal of Orthopaedic Research. 2004;22(5):1126–1134.
[39] Dijkstra G, Blokzijl H, Bok L, et al. Opposite eﬀect of ox-
idative stress on inducible nitric oxide synthase and haem
oxygenase-1 expression in intestinal inﬂammation: anti-
inﬂammatory eﬀe c to fc a rb o nm o n o x i d e .Journal of Pathology.
2004;204(3):296–303.6 Mediators of Inﬂammation
[40] Luongo C, Imperatore F, Cuzzocrea S, et al. Eﬀects of hyper-
baric oxygen exposure on a zymosan-induced shock model.
Critical Care Medicine. 1998;26(12):1972–1976.
[41] Gerschman R, Gilbert D, Nye SW, Dwyer P, Fenn WO. Oxygen
poisoning and X-irradiation: a mechanism in common. 1954.
Nutrition. 2001;17(2):162.
[42] GuoFH,UetaniK,HaqueSJ,etal.Interferonγ andinterleukin
4stimulateprolongedexpressionofinduciblenitricoxidesyn-
thaseinhumanairwayepitheliumthroughsynthesisofsoluble
mediators. Journal of Clinical Investigation. 1997;100(4):829–
838.